A knock-in mutation at cysteine 144 of TRIM72 is cardioprotective and reduces myocardial TRIM72 release

Natasha Fillmore, Kevin M. Casin, Prithvi Sinha, Junhui Sun, Hanley Ma, Jennifer Boylston, Audrey Noguchi, Chengyu Liu, Nadan Wang, Guangshuo Zhou, Mark Kohr, Elizabeth Murphy

Research output: Contribution to journalArticle

Abstract

TRIM72 is a membrane repair protein that protects against ischemia reperfusion (I/R) injury. We previously identified Cys144 (C144) on TRIM72 as a site of S-nitrosylation. To study the importance of C144, we generated a knock-in mouse with C144 mutated to a serine (TRIM72 C144S). We subjected ex vivo perfused mouse hearts to 20 min of ischemia followed by 90 min of reperfusion and observed less injury in TRIM72 C144S compared to WT hearts. Infarct size was smaller (54 vs 27% infarct size) and cardiac functional recovery (37 vs 62% RPP) was higher for the TRIM72 C144S mouse hearts. We also demonstrated that TRIM72 C144S hearts were protected against I/R injury using an in vivo LAD occlusion model. As TRIM72 has been reported to be released from muscle we tested whether C144 is involved in TRIM72 release. After I/R there was significantly less TRIM72 in the perfusate normalized to total released protein from the TRIM72 C144S compared to WT hearts, suggesting that C144 of TRIM72 regulates myocardial TRIM72 release during I/R injury. In addition to TRIM72's protective role in I/R injury, TRIM72 has also been implicated in cardiac hypertrophy and insulin resistance, and secreted TRIM72 has recently been shown to impair insulin sensitivity. However, insulin sensitivity (measured by glucose and insulin tolerance) of TRIM72 C144S mice was not impaired. Further, whole body metabolism, as measured using metabolic cages, was not different in WT vs TRIM72 C144S mice and we did not observe enhanced cardiac hypertrophy in the TRIM72 C144S mice. In agreement, protein levels of the TRIM72 ubiquitination targets insulin receptor β, IRS1, and focal adhesion kinase were similar between WT and TRIM72 C144S hearts. Overall, these data indicate that mutation of TRIM72 C144 is protective during I/R and reduces myocardial TRIM72 release without impairing insulin sensitivity or enhancing the development of hypertrophy.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalJournal of Molecular and Cellular Cardiology
Volume136
DOIs
StatePublished - Nov 1 2019

Fingerprint

Cysteine
Reperfusion Injury
Mutation
Insulin Resistance
Ischemia
Cardiomegaly
Reperfusion
Focal Adhesion Protein-Tyrosine Kinases
Myocardial Reperfusion
Ubiquitination
Insulin Receptor
Serine
Hypertrophy
Membrane Proteins
Proteins
Insulin
Glucose
Muscles
Wounds and Injuries

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

A knock-in mutation at cysteine 144 of TRIM72 is cardioprotective and reduces myocardial TRIM72 release. / Fillmore, Natasha; Casin, Kevin M.; Sinha, Prithvi; Sun, Junhui; Ma, Hanley; Boylston, Jennifer; Noguchi, Audrey; Liu, Chengyu; Wang, Nadan; Zhou, Guangshuo; Kohr, Mark; Murphy, Elizabeth.

In: Journal of Molecular and Cellular Cardiology, Vol. 136, 01.11.2019, p. 95-101.

Research output: Contribution to journalArticle

Fillmore, N, Casin, KM, Sinha, P, Sun, J, Ma, H, Boylston, J, Noguchi, A, Liu, C, Wang, N, Zhou, G, Kohr, M & Murphy, E 2019, 'A knock-in mutation at cysteine 144 of TRIM72 is cardioprotective and reduces myocardial TRIM72 release', Journal of Molecular and Cellular Cardiology, vol. 136, pp. 95-101. https://doi.org/10.1016/j.yjmcc.2019.09.008
Fillmore, Natasha ; Casin, Kevin M. ; Sinha, Prithvi ; Sun, Junhui ; Ma, Hanley ; Boylston, Jennifer ; Noguchi, Audrey ; Liu, Chengyu ; Wang, Nadan ; Zhou, Guangshuo ; Kohr, Mark ; Murphy, Elizabeth. / A knock-in mutation at cysteine 144 of TRIM72 is cardioprotective and reduces myocardial TRIM72 release. In: Journal of Molecular and Cellular Cardiology. 2019 ; Vol. 136. pp. 95-101.
@article{6668fba48e6545419654a7ebaa4ab4e3,
title = "A knock-in mutation at cysteine 144 of TRIM72 is cardioprotective and reduces myocardial TRIM72 release",
abstract = "TRIM72 is a membrane repair protein that protects against ischemia reperfusion (I/R) injury. We previously identified Cys144 (C144) on TRIM72 as a site of S-nitrosylation. To study the importance of C144, we generated a knock-in mouse with C144 mutated to a serine (TRIM72 C144S). We subjected ex vivo perfused mouse hearts to 20 min of ischemia followed by 90 min of reperfusion and observed less injury in TRIM72 C144S compared to WT hearts. Infarct size was smaller (54 vs 27{\%} infarct size) and cardiac functional recovery (37 vs 62{\%} RPP) was higher for the TRIM72 C144S mouse hearts. We also demonstrated that TRIM72 C144S hearts were protected against I/R injury using an in vivo LAD occlusion model. As TRIM72 has been reported to be released from muscle we tested whether C144 is involved in TRIM72 release. After I/R there was significantly less TRIM72 in the perfusate normalized to total released protein from the TRIM72 C144S compared to WT hearts, suggesting that C144 of TRIM72 regulates myocardial TRIM72 release during I/R injury. In addition to TRIM72's protective role in I/R injury, TRIM72 has also been implicated in cardiac hypertrophy and insulin resistance, and secreted TRIM72 has recently been shown to impair insulin sensitivity. However, insulin sensitivity (measured by glucose and insulin tolerance) of TRIM72 C144S mice was not impaired. Further, whole body metabolism, as measured using metabolic cages, was not different in WT vs TRIM72 C144S mice and we did not observe enhanced cardiac hypertrophy in the TRIM72 C144S mice. In agreement, protein levels of the TRIM72 ubiquitination targets insulin receptor β, IRS1, and focal adhesion kinase were similar between WT and TRIM72 C144S hearts. Overall, these data indicate that mutation of TRIM72 C144 is protective during I/R and reduces myocardial TRIM72 release without impairing insulin sensitivity or enhancing the development of hypertrophy.",
author = "Natasha Fillmore and Casin, {Kevin M.} and Prithvi Sinha and Junhui Sun and Hanley Ma and Jennifer Boylston and Audrey Noguchi and Chengyu Liu and Nadan Wang and Guangshuo Zhou and Mark Kohr and Elizabeth Murphy",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.yjmcc.2019.09.008",
language = "English (US)",
volume = "136",
pages = "95--101",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A knock-in mutation at cysteine 144 of TRIM72 is cardioprotective and reduces myocardial TRIM72 release

AU - Fillmore, Natasha

AU - Casin, Kevin M.

AU - Sinha, Prithvi

AU - Sun, Junhui

AU - Ma, Hanley

AU - Boylston, Jennifer

AU - Noguchi, Audrey

AU - Liu, Chengyu

AU - Wang, Nadan

AU - Zhou, Guangshuo

AU - Kohr, Mark

AU - Murphy, Elizabeth

PY - 2019/11/1

Y1 - 2019/11/1

N2 - TRIM72 is a membrane repair protein that protects against ischemia reperfusion (I/R) injury. We previously identified Cys144 (C144) on TRIM72 as a site of S-nitrosylation. To study the importance of C144, we generated a knock-in mouse with C144 mutated to a serine (TRIM72 C144S). We subjected ex vivo perfused mouse hearts to 20 min of ischemia followed by 90 min of reperfusion and observed less injury in TRIM72 C144S compared to WT hearts. Infarct size was smaller (54 vs 27% infarct size) and cardiac functional recovery (37 vs 62% RPP) was higher for the TRIM72 C144S mouse hearts. We also demonstrated that TRIM72 C144S hearts were protected against I/R injury using an in vivo LAD occlusion model. As TRIM72 has been reported to be released from muscle we tested whether C144 is involved in TRIM72 release. After I/R there was significantly less TRIM72 in the perfusate normalized to total released protein from the TRIM72 C144S compared to WT hearts, suggesting that C144 of TRIM72 regulates myocardial TRIM72 release during I/R injury. In addition to TRIM72's protective role in I/R injury, TRIM72 has also been implicated in cardiac hypertrophy and insulin resistance, and secreted TRIM72 has recently been shown to impair insulin sensitivity. However, insulin sensitivity (measured by glucose and insulin tolerance) of TRIM72 C144S mice was not impaired. Further, whole body metabolism, as measured using metabolic cages, was not different in WT vs TRIM72 C144S mice and we did not observe enhanced cardiac hypertrophy in the TRIM72 C144S mice. In agreement, protein levels of the TRIM72 ubiquitination targets insulin receptor β, IRS1, and focal adhesion kinase were similar between WT and TRIM72 C144S hearts. Overall, these data indicate that mutation of TRIM72 C144 is protective during I/R and reduces myocardial TRIM72 release without impairing insulin sensitivity or enhancing the development of hypertrophy.

AB - TRIM72 is a membrane repair protein that protects against ischemia reperfusion (I/R) injury. We previously identified Cys144 (C144) on TRIM72 as a site of S-nitrosylation. To study the importance of C144, we generated a knock-in mouse with C144 mutated to a serine (TRIM72 C144S). We subjected ex vivo perfused mouse hearts to 20 min of ischemia followed by 90 min of reperfusion and observed less injury in TRIM72 C144S compared to WT hearts. Infarct size was smaller (54 vs 27% infarct size) and cardiac functional recovery (37 vs 62% RPP) was higher for the TRIM72 C144S mouse hearts. We also demonstrated that TRIM72 C144S hearts were protected against I/R injury using an in vivo LAD occlusion model. As TRIM72 has been reported to be released from muscle we tested whether C144 is involved in TRIM72 release. After I/R there was significantly less TRIM72 in the perfusate normalized to total released protein from the TRIM72 C144S compared to WT hearts, suggesting that C144 of TRIM72 regulates myocardial TRIM72 release during I/R injury. In addition to TRIM72's protective role in I/R injury, TRIM72 has also been implicated in cardiac hypertrophy and insulin resistance, and secreted TRIM72 has recently been shown to impair insulin sensitivity. However, insulin sensitivity (measured by glucose and insulin tolerance) of TRIM72 C144S mice was not impaired. Further, whole body metabolism, as measured using metabolic cages, was not different in WT vs TRIM72 C144S mice and we did not observe enhanced cardiac hypertrophy in the TRIM72 C144S mice. In agreement, protein levels of the TRIM72 ubiquitination targets insulin receptor β, IRS1, and focal adhesion kinase were similar between WT and TRIM72 C144S hearts. Overall, these data indicate that mutation of TRIM72 C144 is protective during I/R and reduces myocardial TRIM72 release without impairing insulin sensitivity or enhancing the development of hypertrophy.

UR - http://www.scopus.com/inward/record.url?scp=85073160010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073160010&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2019.09.008

DO - 10.1016/j.yjmcc.2019.09.008

M3 - Article

C2 - 31536744

AN - SCOPUS:85073160010

VL - 136

SP - 95

EP - 101

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -